JnJ HIV vaccine fails Imbokodo trial
The Imbokodo study showed a 25.2% vaccine efficacy, based on which, the drugmaker said the study will not continue.;
New Delhi: Johnson & Johnson's experimental vaccine failed to provide sufficient protection against HIV to young women in sub-Saharan Africa, in the latest setback to the field after a string of earlier failures.
The mid-stage study called Imbokodo, testing the experimental J&J vaccine, included 2,600 women participants across five Southern African countries, where women and girls accounted for over 60% of all new HIV infections last year.
J&J said it was continuing to study the safety and efficacy of a different experimental HIV vaccine among men who have sex with men, and transgender persons. That trial, conducted in the Americas and Europe, is expected to be completed in March 2024.
Despite the discovery of effective treatments that can put the virus in remission, experts say an HIV vaccine is critical to eradicating the virus that causes AIDS, which resulted in 680,000 deaths last year.
Read also: Second dose provides strong boost against Covid-19: JnJ
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.